NK cells, immunotherapy, and chemo before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding natural killer (NK) cell therapy to standard chemo and immunotherapy before surgery for stage IB to IIIA non-small cell lung cancer that can be removed. It aims to see if this combination helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that is stage IB to IIIA and can be removed with surgery.
- You have not had any prior cancer treatment for this lung cancer.
- Your cancer does not have certain EGFR gene mutations or ALK gene rearrangements.
- You are 18 years or older and in good overall health (able to do daily activities without help).
- You do not have an active autoimmune disease, interstitial lung disease, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
This trial tests giving chemotherapy combined with the immunotherapy drug sintilimab before surgery for people with stage IIA to IIIB non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.